Botulinum toxin injection changes resting state cerebellar connectivity in cervical dystonia.
Adult
Botulinum Toxins, Type A
/ administration & dosage
Cerebellum
/ physiopathology
Cerebral Cortex
/ physiopathology
Cognition
/ physiology
Female
Humans
Injections, Intralesional
Magnetic Resonance Imaging
Male
Middle Aged
Rest
/ physiology
Severity of Illness Index
Torticollis
/ diagnostic imaging
Treatment Outcome
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 04 2021
15 04 2021
Historique:
received:
20
06
2020
accepted:
19
03
2021
entrez:
16
4
2021
pubmed:
17
4
2021
medline:
19
11
2021
Statut:
epublish
Résumé
In cervical dystonia, functional MRI (fMRI) evidence indicates changes in several resting state networks, which revert in part following the botulinum neurotoxin A (BoNT) therapy. Recently, the involvement of the cerebellum in dystonia has gained attention. The aim of our study was to compare connectivity between cerebellar subdivisions and the rest of the brain before and after BoNT treatment. Seventeen patients with cervical dystonia indicated for treatment with BoNT were enrolled (14 female, aged 50.2 ± 8.5 years, range 38-63 years). Clinical and fMRI examinations were carried out before and 4 weeks after BoNT injection. Clinical severity was evaluated using TWSTRS. Functional MRI data were acquired on a 1.5 T scanner during 8 min rest. Seed-based functional connectivity analysis was performed using data extracted from atlas-defined cerebellar areas in both datasets. Clinical scores demonstrated satisfactory BoNT effect. After treatment, connectivity decreased between the vermis lobule VIIIa and the left dorsal mesial frontal cortex. Positive correlations between the connectivity differences and the clinical improvement were detected for the right lobule VI, right crus II, vermis VIIIb and the right lobule IX. Our data provide evidence for modulation of cerebello-cortical connectivity resulting from successful treatment by botulinum neurotoxin.
Identifiants
pubmed: 33859210
doi: 10.1038/s41598-021-87088-z
pii: 10.1038/s41598-021-87088-z
pmc: PMC8050264
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8322Références
Cerebellum. 2017 Apr;16(2):577-594
pubmed: 27734238
Sci Rep. 2018 Nov 21;8(1):17218
pubmed: 30464181
Mov Disord. 1998 Jan;13(1):108-17
pubmed: 9452335
Neuroimage Clin. 2019;22:101792
pubmed: 30928809
Ann Neurol. 1991 Apr;29(4):370-6
pubmed: 1929208
Neuroimage. 2015 May 15;112:267-277
pubmed: 25770991
Front Neurosci. 2019 Jul 17;13:722
pubmed: 31379481
Hum Brain Mapp. 2020 Aug 15;41(12):3253-3265
pubmed: 32311207
Mov Disord. 2011 Aug 15;26(10):1907-12
pubmed: 21717508
Brain Struct Funct. 2015 Jan;220(1):513-23
pubmed: 24259114
Neural Plast. 2019 Apr 24;2019:7349894
pubmed: 31178903
Eur J Neurol. 1997 Jan;4(1):79-84
pubmed: 24283826
Hum Brain Mapp. 2017 Aug;38(8):4098-4108
pubmed: 28504361
Ann Neurol. 2000 Jul;48(1):20-6
pubmed: 10894212
J Neurol Sci. 2019 Apr 15;399:44-50
pubmed: 30771702
Mov Disord. 2014 Aug;29(9):1141-50
pubmed: 24925463
Neuron. 2019 Jun 5;102(5):918-928
pubmed: 31170400
Neurotox Res. 2006 Apr;9(2-3):109-14
pubmed: 16785106
Cereb Cortex. 2017 Feb 1;27(2):1203-1215
pubmed: 26679193
BMC Neurosci. 2013 Oct 16;14:123
pubmed: 24131497
Clin Neurophysiol. 2013 Jul;124(7):1269-76
pubmed: 23422326
Clin Neurophysiol. 2012 Jan;123(1):65-70
pubmed: 22078259
Clin Neurol Neurosurg. 2008 Feb;110(2):120-8
pubmed: 18006221
Brain. 2019 Jun 1;142(6):1660-1674
pubmed: 31099831
Int J Neurosci. 2012 Jan;122(1):45-52
pubmed: 21919815
Eur J Neurol. 2021 May;28(5):1537-1547
pubmed: 33350546
Neuroimage. 2004 Apr;21(4):1732-47
pubmed: 15050594
J Neurol. 2020 Apr;267(4):1103-1115
pubmed: 31897600
Neurology. 2020 Oct 20;95(16):e2246-e2258
pubmed: 32913023
Neuroimage. 2009 May 15;46(1):39-46
pubmed: 19457380
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Front Neurol. 2019 Aug 27;10:914
pubmed: 31507518
J Neurophysiol. 2011 Nov;106(5):2322-45
pubmed: 21795627
Neuroimage. 2007 Jul 1;36(3):511-21
pubmed: 17499520
Neuroscience. 2014 Feb 28;260:23-35
pubmed: 24333801
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
PLoS One. 2013 May 01;8(5):e62877
pubmed: 23650536
Mov Disord. 2013 Jun 15;28(7):944-57
pubmed: 23893451
Med Image Comput Comput Assist Interv. 2006;9(Pt 2):58-66
pubmed: 17354756
Neuroimage. 2001 Dec;14(6):1370-86
pubmed: 11707093
Handb Exp Pharmacol. 2021;263:107-126
pubmed: 31820178
Exp Neurol. 2013 Mar;241:95-104
pubmed: 23195594
J Physiol. 2013 Feb 15;591(4):1017-29
pubmed: 23045348
Mov Disord. 2004 Mar;19 Suppl 8:S109-15
pubmed: 15027062
Parkinsonism Relat Disord. 2014 Feb;20(2):198-203
pubmed: 24262871
Nat Rev Dis Primers. 2018 Sep 20;4(1):25
pubmed: 30237473
J Neurophysiol. 2008 Dec;100(6):3328-42
pubmed: 18799601
Mov Disord. 2017 May;32(5):757-768
pubmed: 28186664
J Neurol. 1992 Jan;239(1):9-15
pubmed: 1541974
J Neurol Sci. 2011 Jul 15;306(1-2):71-5
pubmed: 21492880
Exp Brain Res. 2018 Oct;236(10):2627-2637
pubmed: 29971454
Front Neurol. 2016 Nov 15;7:201
pubmed: 27895619
Neurobiol Dis. 2011 May;42(2):185-201
pubmed: 21303695